Dear Editor,Acute Myeloid Leukemia(AML)patients are often found ineligible for aggressive standard chemotherapy in clinic because of old age and poor conditions.Current evidences suggest that targeted combination ther...Dear Editor,Acute Myeloid Leukemia(AML)patients are often found ineligible for aggressive standard chemotherapy in clinic because of old age and poor conditions.Current evidences suggest that targeted combination therapy might help these patients achieve a higher response rate with acceptable adverse events(AEs).^(1)Venetoclax(VEN),a selective small-molecule BCL2 inhibitor,combined with hypomethylating agent(HMA),such as azacytidine(AZA).展开更多
文摘Dear Editor,Acute Myeloid Leukemia(AML)patients are often found ineligible for aggressive standard chemotherapy in clinic because of old age and poor conditions.Current evidences suggest that targeted combination therapy might help these patients achieve a higher response rate with acceptable adverse events(AEs).^(1)Venetoclax(VEN),a selective small-molecule BCL2 inhibitor,combined with hypomethylating agent(HMA),such as azacytidine(AZA).
